Insider Activity: Vail Resorts CEO Invests $4.9 Million in Company Shares

Overview of Insider Activity#

On Monday, several notable insider buying and selling activities were reported among U.S. public companies, showcasing significant investments by company executives and investment firms.

Vail Resorts CEO Makes a Major Purchase#

Robert A. Katz, the CEO and Chairperson of Vail Resorts (NASDAQ:MTN), bought 37,500 shares of the company’s stock on March 16, 2026. The shares were purchased at an average price of $131.81, totaling approximately $4.9 million. The prices for these shares ranged from $131.37 to $131.88. Following this transaction, Katz now owns 285,312 shares of Vail Resorts. This purchase occurs as the stock is trading near its 52-week low of $126.16, indicating a potential opportunity according to some analysts who suggest the stock may be undervalued.

General Atlantic Invests in Alkami Technology#

General Atlantic, a group of investment firms, purchased 500,000 shares of Alkami Technology, Inc. (NASDAQ:ALKT) on March 12, 2026, at an average price of $18.33, amounting to $9.165 million. The shares were bought in multiple transactions with prices between $18.30 and $18.36. After this acquisition, General Atlantic holds a total of 15,379,451 shares of Alkami Technology. Despite a 32% decline in the stock price over the past six months, analysts believe the company could become profitable this year, suggesting a potential turnaround.

ContextLogic Holdings Director Acquires Shares#

Bobbili Raja, a director at ContextLogic Holdings Inc (NASDAQ:LOGC), bought 71,000 shares between March 12 and March 16, 2026, for a total of $585,058. The shares were purchased at prices ranging from $8.00 to $8.34. This series of transactions indicates confidence in the company's future prospects.

TCG Crossover Funds Invest in Surrozen#

TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P. reported purchasing shares of Surrozen, Inc. (NASDAQ:SRZN) in transactions totaling $1.2 million, with share prices ranging from $24.8769 to $24.9857. These purchases reflect ongoing interest from investment firms in the biotechnology sector.